Rare Disease Biopharma can now sell Hemophilia treatment across whole of EU

17/05/2016 - 2 minutes

Sobi has received market approval by the European Comission for Alprolix, a long-duration protein therapy that protects hemophilia B patients from uncontrolled bleeding. 

sobi_hemophilia_b_factor_ix_alprolixWith a focus on rare diseases, Swedish Orphan Biovitrum (Sobi) has clinical programmes in diseases like alkaptonuria, tyrosinaemia and hemophilia – a disease with which Sobi is particularly invested.

Its candidate for hemophilia B (Alprolix) was one of the most advanced. Its long term studies have shown good results, with two phase III trials – B-Long with 123 adult patients and Kids B-Long for children under 12.

Now, Alprolix (rFIXFc) has been approved by the European Commission (EC). It will be available in all 28 countries of the EU, where it’s the only treatment of its kind for hemophilia B.

The therapy is a recombinant protein that replaces a clotting factor (IX)- which is not naturally expressed in patients. 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member